1. Home
  2. AVDL vs MGIC Comparison

AVDL vs MGIC Comparison

Compare AVDL & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • MGIC
  • Stock Information
  • Founded
  • AVDL 2015
  • MGIC 1983
  • Country
  • AVDL Ireland
  • MGIC Israel
  • Employees
  • AVDL N/A
  • MGIC N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • MGIC Computer Software: Prepackaged Software
  • Sector
  • AVDL Health Care
  • MGIC Technology
  • Exchange
  • AVDL Nasdaq
  • MGIC Nasdaq
  • Market Cap
  • AVDL 900.2M
  • MGIC 788.0M
  • IPO Year
  • AVDL 1996
  • MGIC 1991
  • Fundamental
  • Price
  • AVDL $9.54
  • MGIC $21.42
  • Analyst Decision
  • AVDL Strong Buy
  • MGIC Buy
  • Analyst Count
  • AVDL 6
  • MGIC 2
  • Target Price
  • AVDL $18.17
  • MGIC $16.00
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • MGIC 89.2K
  • Earning Date
  • AVDL 08-07-2025
  • MGIC 08-13-2025
  • Dividend Yield
  • AVDL N/A
  • MGIC 2.62%
  • EPS Growth
  • AVDL N/A
  • MGIC 1.33
  • EPS
  • AVDL N/A
  • MGIC 0.76
  • Revenue
  • AVDL $194,450,000.00
  • MGIC $569,136,000.00
  • Revenue This Year
  • AVDL $56.88
  • MGIC $7.53
  • Revenue Next Year
  • AVDL $29.81
  • MGIC $8.96
  • P/E Ratio
  • AVDL N/A
  • MGIC $28.38
  • Revenue Growth
  • AVDL 252.64
  • MGIC 6.37
  • 52 Week Low
  • AVDL $6.38
  • MGIC $9.64
  • 52 Week High
  • AVDL $17.30
  • MGIC $22.00
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 56.42
  • MGIC 79.63
  • Support Level
  • AVDL $8.74
  • MGIC $20.17
  • Resistance Level
  • AVDL $9.56
  • MGIC $22.00
  • Average True Range (ATR)
  • AVDL 0.39
  • MGIC 0.57
  • MACD
  • AVDL 0.04
  • MGIC 0.25
  • Stochastic Oscillator
  • AVDL 81.92
  • MGIC 90.52

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About MGIC Magic Software Enterprises Ltd.

Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.

Share on Social Networks: